A Randomized Controlled Trial to Compare the Effectiveness of Fecal Microbiota Transplantation (FMT) in Combination With Bezlotoxumab Compared to FMT and Placebo for the Prevention of CDI Recurrence in Patients With Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection
Latest Information Update: 18 Dec 2025
At a glance
- Drugs Bezlotoxumab (Primary)
- Indications Clostridium difficile infections; Inflammatory bowel diseases
- Focus Therapeutic Use
- Acronyms ICON-2
Most Recent Events
- 09 Dec 2025 Status changed from recruiting to completed.
- 06 Aug 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2025.
- 06 Aug 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Sep 2024.